IF 2 4区 医学Q3 MEDICINE, RESEARCH & EXPERIMENTALDiscovery medicinePub Date : 2022-11-01
Chaowei Gao, Jiangen Wang, Peisheng He, Xin Xiong
{"title":"乳腺癌的组织学分级转移模式:一项基于SEER人群的研究。","authors":"Chaowei Gao, Jiangen Wang, Peisheng He, Xin Xiong","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Population-based estimates of the differences -in metastatic pattern, incidence, and prognosis of breast cancer patients by histologic grade at breast cancer diagnosis are lacking. Patients with breast cancer and metastases at the time of diagnosis were identified using the Surveillance, Epidemiology, and End Results (SEER) database. Multivariable logistic and Cox regression were performed to determine the effect of histologic grade on the presence of metastases at diagnosis and all-cause mortality. We identified a population-based sample of adult patients diagnosed with invasive breast cancer between 2010 and 2015 for whom the presence or absence of metastases was known. We depicted the landscape of metastatic pattern of breast cancer histologic grade that the percentage of bone metastasis was decreasing with higher histologic grade, while the percentages of lung and brain metastasis were increasing. Higher histologic grade was associated with a greater incidence of all metastatic lesions. Median durations of survival with distant metastasis were 41 months (Grade I), 34 months (Grade II), 21 months (Grade III), 13 months (Grade IV), and 16 months (unknown histologic grade). Grade III and unknown histologic grade represent the most common part of patients with metastatic disease, but not for breast cancer patients without metastasis. In multivariate analysis, Grade II, III, IV, and unknown histologic grade were associated with significantly greater odds of patients with metastatic disease to any distant site, compared with Grade I, but not to bone. Grade III was associated with increased all-cause mortality among patients having metastases to any sites, bone, brain, liver, and lung compared with Grade I, but not Grade II and Grade IV. Breast cancer histologic grades are associated with distinct patterns of metastatic spread and notable differences in survival.</p>","PeriodicalId":11379,"journal":{"name":"Discovery medicine","volume":"34 173","pages":"189-197"},"PeriodicalIF":2.0000,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Metastatic Pattern of Breast Cancer by Histologic Grade: A SEER Population-based Study.\",\"authors\":\"Chaowei Gao, Jiangen Wang, Peisheng He, Xin Xiong\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Population-based estimates of the differences -in metastatic pattern, incidence, and prognosis of breast cancer patients by histologic grade at breast cancer diagnosis are lacking. Patients with breast cancer and metastases at the time of diagnosis were identified using the Surveillance, Epidemiology, and End Results (SEER) database. Multivariable logistic and Cox regression were performed to determine the effect of histologic grade on the presence of metastases at diagnosis and all-cause mortality. We identified a population-based sample of adult patients diagnosed with invasive breast cancer between 2010 and 2015 for whom the presence or absence of metastases was known. We depicted the landscape of metastatic pattern of breast cancer histologic grade that the percentage of bone metastasis was decreasing with higher histologic grade, while the percentages of lung and brain metastasis were increasing. Higher histologic grade was associated with a greater incidence of all metastatic lesions. Median durations of survival with distant metastasis were 41 months (Grade I), 34 months (Grade II), 21 months (Grade III), 13 months (Grade IV), and 16 months (unknown histologic grade). Grade III and unknown histologic grade represent the most common part of patients with metastatic disease, but not for breast cancer patients without metastasis. In multivariate analysis, Grade II, III, IV, and unknown histologic grade were associated with significantly greater odds of patients with metastatic disease to any distant site, compared with Grade I, but not to bone. Grade III was associated with increased all-cause mortality among patients having metastases to any sites, bone, brain, liver, and lung compared with Grade I, but not Grade II and Grade IV. Breast cancer histologic grades are associated with distinct patterns of metastatic spread and notable differences in survival.</p>\",\"PeriodicalId\":11379,\"journal\":{\"name\":\"Discovery medicine\",\"volume\":\"34 173\",\"pages\":\"189-197\"},\"PeriodicalIF\":2.0000,\"publicationDate\":\"2022-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Discovery medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Discovery medicine","FirstCategoryId":"3","ListUrlMain":"","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
Metastatic Pattern of Breast Cancer by Histologic Grade: A SEER Population-based Study.
Population-based estimates of the differences -in metastatic pattern, incidence, and prognosis of breast cancer patients by histologic grade at breast cancer diagnosis are lacking. Patients with breast cancer and metastases at the time of diagnosis were identified using the Surveillance, Epidemiology, and End Results (SEER) database. Multivariable logistic and Cox regression were performed to determine the effect of histologic grade on the presence of metastases at diagnosis and all-cause mortality. We identified a population-based sample of adult patients diagnosed with invasive breast cancer between 2010 and 2015 for whom the presence or absence of metastases was known. We depicted the landscape of metastatic pattern of breast cancer histologic grade that the percentage of bone metastasis was decreasing with higher histologic grade, while the percentages of lung and brain metastasis were increasing. Higher histologic grade was associated with a greater incidence of all metastatic lesions. Median durations of survival with distant metastasis were 41 months (Grade I), 34 months (Grade II), 21 months (Grade III), 13 months (Grade IV), and 16 months (unknown histologic grade). Grade III and unknown histologic grade represent the most common part of patients with metastatic disease, but not for breast cancer patients without metastasis. In multivariate analysis, Grade II, III, IV, and unknown histologic grade were associated with significantly greater odds of patients with metastatic disease to any distant site, compared with Grade I, but not to bone. Grade III was associated with increased all-cause mortality among patients having metastases to any sites, bone, brain, liver, and lung compared with Grade I, but not Grade II and Grade IV. Breast cancer histologic grades are associated with distinct patterns of metastatic spread and notable differences in survival.
期刊介绍:
Discovery Medicine publishes novel, provocative ideas and research findings that challenge conventional notions about disease mechanisms, diagnosis, treatment, or any of the life sciences subjects. It publishes cutting-edge, reliable, and authoritative information in all branches of life sciences but primarily in the following areas: Novel therapies and diagnostics (approved or experimental); innovative ideas, research technologies, and translational research that will give rise to the next generation of new drugs and therapies; breakthrough understanding of mechanism of disease, biology, and physiology; and commercialization of biomedical discoveries pertaining to the development of new drugs, therapies, medical devices, and research technology.